Philip Louis McCarthy MD

Hematology•Buffalo, NY

Hematologic Oncology

Professor of Oncology and Internal Medicine, Roswell Park Cancer Institute and SUNY at Buffalo School of Medicine

Join to View Full Profile

Elm and Carlton StBuffalo, NY 14263
Phone+1 716-845-2300
Fax+1 716-845-3272

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1985 - 1989
Yale-New Haven Medical CenterResidency, Internal Medicine, 1982 - 1985
Tufts University School of MedicineClass of 1982

Certifications & Licensure

NY State Medical License 1996 - 2025
MA State Medical License 1987 - 2016
TX State Medical License 1992 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Start of enrollment: 1998 Oct 19
Completed
Phase 2, Phase 3
Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer Start of enrollment: 1998 Sep 01
Completed
Phase 1, Phase 2
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia Start of enrollment: 2002 Jun 01
Completed
Not Applicable
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders Start of enrollment: 2002 Jan 29
Completed
Phase 2
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Start of enrollment: 2003 Jan 01
Completed
Phase 2
Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract Start of enrollment: 2001 Mar 01
Completed
Not Applicable
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors Start of enrollment: 1991 Dec 01
Completed
Phase 2
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant Start of enrollment: 2004 Dec 15
ACTIVE_NOT_RECRUITING
PHASE3
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2005 Apr 27
Completed
Phase 2
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant Start of enrollment: 2003 Oct 01
Completed
Not Applicable
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors Start of enrollment: 2006 Jun 29
Completed
Not Applicable
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant Start of enrollment: 2012 May 01
Withdrawn
Not Applicable
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant Start of enrollment: 2019 Dec 19
Completed
Phase 2
MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Active, not recruiting
Phase 2
Roles: Contact
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Active, not recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702.
Rahul Banerjee, Amber R Fritz, Othman S Akhtar, Ciara L Freeman, Andrew J Cowan
Leukemia. 2025-02-24
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class ...
Gayathri Ravi, Shambavi Richard, Shaji Kumar, Shebli Atrash, Michaela Liedtke
Leukemia. 2025-02-05
1 citations
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.
Peter Voorhees, Vera Suman, Yvonne Efebera, Noopur Raje, Sascha Tuchman
Blood Advances. 2024-10-08

Abstracts/Posters

Genome Wide Interaction Analysis Identifies Expression Quantitative Trait Loci Associated with Reduced Survival after Reduced Intensity Conditioning HLA-Matched Unrela...
Philip L. McCarthy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Tran...
Philip L. McCarthy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
Philip L. McCarthy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
_2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogenic Transplantation While Preserving Graft Versus Leukemia Effect
Philip L. McCarthy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Genome Wide Association Analyses Identify Pleiotropic Variants Associated with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Susceptibility
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Castle Connolly Names 38 Roswell Park Physicians to ‘Top Doctors’ ListFebruary 2nd, 2023
Roswell Park Oncology Experts Named to Castle Connolly ‘Top Doctors’ ListAugust 4th, 2022
Roswell Park Researchers Identify Key Link Between Stress and CancerNovember 5th, 2021
Join now to see all